Skip to main content

Advertisement

Table 1 Demographic, functional and therapeutic characteristics

From: Increased of exhaled breath condensate neutrophil chemotaxis in acute exacerbation of COPD

  Healthy controls Stable COPD patients Exacerbated COPD patients
Outpatients Hospitalized
No of subjects 20 17 16 17
Age (yrs) 57.1 ± 8.7 59.8 ± 7.4 61.8 ± 6.4 63.8 ± 8.4
Male/female number 8/3 13/4 13/3 13/4
BMI (kg/m2) 24.2 ± 3.3 25.8 ± 3.4 26.1 ± 4.8 26.7 ± 7.1
Number of pack years 25.2 ± 13.8 41.3 ± 18.9 † 41.4 ± 11.8 † 43.3 ± 14.3 ††
FEV1,% predicted value 99.6 ± 14.8 52.5 ± 18.0 ††† 48.1 ± 11.6 ††† 37.0 ± 14.1 †††*
FEV1/FVC% 77.5 ± 4.7 50.7 ± 11.7 ††† 47.0 ± 13.3 ††† 46.2 ± 9.5 †††
GOLD stages No     
GOLD 2   11 10 4*#
GOLD 3-4   6 6 13*#
Inhaled corticosteroid     
Number   13 15 14
Mean daily dose of ICSμg   1235.3 ± 877.1 1421.9 ± 553.2 1588.2 ± 678.6
Long-acting B2 agonist, number   13 15 14
Long-acting Anticholinergic, number   15 14 16
Oral steroids¶¶, number   0 0 17
  1. Data are expressed as means ± SD.
  2. Expressed as beclomethasone equivalent (In converting corticosteroid drugs to a beclomethasone equivalent, we assumed that 1 mg of beclomethasone was equivalent to 0.8 mg of budesonide, 0.5 mg of fluticasone).
  3. ¶¶Taken at the moment of sampling.
  4. p < 0.05, †† p <0.01, ††† p < 0.001 vs controls. *p < 0.05 vs stable COPD, #p < 0.05 vs outpatients with exacerbation of COPD.
  5. COPD: chronic obstructive pulmonary disease; BMI: body mass index; FEV1: forced expiratory volume in one second; FVC: forced vital capacity.